4.8 Article

A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness

Journal

ONCOGENE
Volume 36, Issue 50, Pages 6919-6928

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2017.305

Keywords

-

Funding

  1. Hormel Foundation
  2. National Cancer Institute (Bethesda, MD, USA) [R01CA149623, R21CA155915]

Ask authors/readers for more resources

Overexpression of DNMT1 and KIT is prevalent in lung cancer, yet the underlying molecular mechanisms are poorly understood. While the deregulated activation of DNMT1 or KIT has been implicated in lung cancer pathogenesis, whether and how DNMT1 and KIT orchestrate lung tumorigenesis are unclear. Here, using human lung cancer tissue microarrays and fresh frozen tissues, we found that the overexpression of DNMT1 is positively correlated with the upregulation of KIT in tumor tissues. We demonstrated that DNMT1 and KIT form a positive regulatory loop, in which ectopic DNMT1 expression increases, whereas targeted DNMT1 depletion abrogates KIT signaling cascade through Sp1/miR-29b network. Conversely, an increase of KIT levels augments, but a reduction of KIT expression ablates DNMT1 transcription by STAT3 pathway leading to in-parallel modification of the DNA methylation profiles. We provided evidence that KIT inactivation induces global DNA hypomethylation, restores the expression of tumor suppressor p15(INK4B) through promoter demethylation; in turn, DNMT1 dysfunction impairs KIT kinase signaling. Functionally, KIT and DNMT1 co-expression promotes, whereas dual inactivation of them suppresses, lung cancer cell proliferation and metastatic growth in vitro and in vivo, in a synergistic manner. These findings demonstrate the regulatory and functional interplay between DNA methylation and tyrosine kinase signaling in propelling tumorigenesis, providing a widely applicable approach for targeting lung cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Exendin-4 may improve type 2 diabetes by modulating the epigenetic modifications of pancreatic histone H3 in STZ-induced diabetic C57BL/6 J mice

Peipei Tu, Bin Huang, Minggang Li, Yaofang Zhang, Shixiang Bao, Na Tu, Yanan Yang, Jingtao Lu

Summary: Type 2 diabetes (T2D) is a complex systemic disease that might benefit from treatment with exendin-4, as shown in this study on C57BL/6 J mice. The study investigated epigenetic alterations in pancreatic tissues of diabetic mice and demonstrated an improvement in T2D progression with exendin-4 treatment through modulation of histone acetylation and methylation patterns. Understanding these epigenetic changes may lead to novel therapeutic approaches for T2D.

JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2022)

Article Medicine, Research & Experimental

Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy

Hongqiao Cai, Ruobing Wang, Xingren Guo, Meiyu Song, Fei Yan, Bai Ji, Yahui Liu

Summary: The combination of gemcitabine-loaded PLGA nanoparticles with a macrophage membrane coating showed promising results in reducing drug toxicity, improving tumor accumulation, and inhibiting pancreatic cancer cell proliferation through targeting signaling pathways. This approach provides potential synergistic anti-tumor efficacy for treating pancreatic cancer.

MOLECULAR PHARMACEUTICS (2021)

Article Chemistry, Multidisciplinary

Tumor-Associated-Macrophage-Membrane-Coated Nanoparticles for Improved Photodynamic Immunotherapy

Cailing Chen, Meiyu Song, Yangyang Du, Ying Yu, Chunguang Li, Yu Han, Fei Yan, Zhan Shi, Shouhua Feng

Summary: Cell-membrane-coated nanoparticles, particularly those derived from tumor-associated macrophages (TAMM), show promise as an antitumor therapeutic strategy. TAMM exhibit unique antigen-homing affinity capacity and immune compatibility, with potential to enhance antitumor immunity efficiency via activation of antigen-presenting cells and production of tumor-specific effector T cells in metastatic tumors. TAM-membrane-based photodynamic immunotherapy offers a new personalized approach to tumor therapy.

NANO LETTERS (2021)

Article Chemistry, Multidisciplinary

Hepcidin-Based Nanocomposites for Enhanced Cancer Immunotherapy by Modulating Iron Export-Mediated N6-Methyladenosine RNA Transcript

Lingxiao Zhang, Yue Song, Kunxia Cao, Yangyang Du, Mingda Han, Zhan Shi, Fei Yan, Shouhua Feng

Summary: Despite recent advances in targeted therapies and immunotherapies in acute myeloid leukemia, ferrotherapy using iron-based compounds offers a novel approach to bypass chemoresistance. However, overexpression of ferroportin in cancer cells may limit the efficacy of ferrotherapy and lead to systemic toxic effects. The development of a hepcidin-based nanocomposite shows promise as an epigenetic drug and immunotherapeutic agent for treating leukemia.

ADVANCED FUNCTIONAL MATERIALS (2022)

Article Chemistry, Multidisciplinary

Glutathione-Bioimprinted Nanoparticles Targeting of N6-methyladenosine FTO Demethylase as a Strategy against Leukemic Stem Cells

Kunxia Cao, Yangyang Du, Xin Bao, Mingda Han, Rui Su, Jiuxia Pang, Shujun Liu, Zhan Shi, Fei Yan, Shouhua Feng

Summary: In this study, FTO inhibitor-loaded GSH-bioimprinted nanocomposites were developed to selectively target leukemia cells, especially leukemia stem cells (LSCs), and induce cell death by disrupting intracellular redox status. Additionally, the nanocomposites increased m(6)A RNA modification levels and enhanced the efficacy of immune therapy.

SMALL (2022)

Article Engineering, Biomedical

Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy

Qing Li, Rui Su, Xin Bao, Kunxia Cao, Yangyang Du, Nanya Wang, Jianfeng Wang, Fan Xing, Fei Yan, Keke Huang, Shouhua Feng

Summary: Programmed cell death protein 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) blockade immunotherapy is limited by low response rates in many patients. This study developed a nanoplatform that induces immunogenic cell death and enhances tumor immunotherapy through synergistic effects with ferrotherapy. The combination of glycyrrhetinic acid-based nanomaterials and ferumoxytol improved T-cell immune response and showed potential for treating cancer.

ACTA BIOMATERIALIA (2022)

Article Materials Science, Multidisciplinary

Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy

Xinlun Dai, Xin Li, Yahui Liu, Fei Yan

Summary: This article discusses the progress in anti-tumor immune checkpoint blockade (ICB) therapy and nanoparticle-mediated photothermal therapy (PTT), as well as the pre-clinical trials of combined PTT/ICB therapy. Nanoparticles offer advantages such as increased tumor-targeting ability, high drug-loading capacity, and satisfactory biocompatibility, which can enhance the anti-tumor effects when combined with ICB therapy.

MATERIALS & DESIGN (2022)

Review Immunology

A diversified role for γδT cells in vector-borne diseases

Chen Chen, Aibao Chen, Yanan Yang

Summary: Vector-borne diseases pose major health threats globally, and γδT cells play a crucial role in regulating host-pathogen interactions and disease progression.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer

Yan Li, Lihong Fan, Jianming Zheng, Xiu Nie, Yu Sun, Qin Feng, Shenyi Lian, Wenqi Bai, Weijing Cai, Yanan Yang, Bo Su, Yanfeng Xi, Dongmei Lin

Summary: This study systematically investigated the pre-screening methods and characterized the genetic and clinical features of Lynch syndrome (LS) colorectal cancers (CRCs) in Asia. The results demonstrated that MMR IHC and MSI testing were effective methods for LS pre-screening and identified previously unreported pathogenic germline variants of MMR genes in LS patients.

CANCER BIOLOGY & MEDICINE (2022)

Article Nanoscience & Nanotechnology

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N6-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Jianhua Liu, Yue Song, Yiqiao Wang, Mingda Han, Chunxi Wang, Fei Yan

Summary: Cancer immunotherapy has shown great potential in treating metastatic tumors and preventing recurrence. However, the limitations of low patient response rates and toxicity have hindered its effectiveness. This study presents a nanoplatform using gold nanorods for enhanced photothermal immunotherapy against prostate cancer by combining NIR-II-mediated photothermal therapy and N-6-methyladenosine (m(6)A) demethylase inhibition. The results show that the nanoplatform specifically targets prostate tumor cells and successfully eliminates tumors under laser irradiation. Mechanistically, the nanoplatform triggers the release of the demethylase inhibitor, leading to increased mRNA methylation and decreased stability of PDL1 transcripts. The study suggests that this synergistic approach could be an effective strategy for cancer immunotherapy.

ACS APPLIED MATERIALS & INTERFACES (2022)

Article Engineering, Environmental

Targeting N6-methyladenosine reader YTHDF1 promotes second near-infrared Nano-Photothermal immunotherapy

Yangyang Du, Xinlun Dai, Mingda Han, Zhihua Wang, Yiqiao Wang, Zhan Shi, Fei Yan, Shouhua Feng

Summary: This article introduces a photothermal immunotherapy method triggered by near-infrared light, which shows promise in cancer treatment. By combining gene expression modification and immune cell activation, the study successfully inhibits primary tumor growth, suppresses metastasis, and prevents tumor recurrence.

CHEMICAL ENGINEERING JOURNAL (2023)

Article Chemistry, Multidisciplinary

A Bimetallic Metal-Organic-Framework-Based Biomimetic Nanoplatform Enhances Anti-Leukemia Immunity via Synchronizing DNA Demethylation and RNA Hypermethylation

Yue Song, Lingxiao Zhang, Yiqiao Wang, Mingda Han, Zhihua Wang, Ning Wang, Bingru Shao, Runan Li, Kunxia Cao, Meiyu Song, Yangyang Du, Fei Yan

Summary: A bimetallic metal-organic framework (MOF)-based biomimetic nanoplatform, AFMMB, is developed for dual epigenetic therapy against cancer. AFMMB selectively targets leukemic cells and leukemia stem cells, thereby enhancing T-cell-mediated immune response through the induction of autophagy and inhibition of DNA methylation. AFMMB also shows potential for suppressing the growth and metastasis of solid tumors, indicating a pan-cancer effect. Clinical validation of AFMMB is warranted.

ADVANCED MATERIALS (2023)

Article Engineering, Environmental

Gold Nanorod-mesoporous silica core shell nanocomposites for NIR-II photothermal ablation and dual PD-L1/VEGF blockade therapy in hepatocellular carcinoma

Xinlun Dai, Xin Li, Yangyang Du, Mingda Han, Zhihua Wang, Yiqiao Wang, Fei Yan, Yahui Liu

Summary: A nanoplatform (GSBVVP) combining photothermal therapy (PTT) with dual blockade of VEGF and PD-L1 was designed to enhance the immune response for HCC treatment. This nanoplatform released a PD-L1 inhibitor upon NIR-II triggering, increasing the infiltration of CD8+ T cells and inhibiting VEGF secretion by tumor cells. Animal studies showed that GSBVVP-mediated photothermal immunotherapy significantly inhibited tumor growth, metastasis, and recurrence.

CHEMICAL ENGINEERING JOURNAL (2023)

Article Nanoscience & Nanotechnology

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N6-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Jianhua Liu, Yue Song, Yiqiao Wang, Mingda Han, Chunxi Wang, Fei Yan

Summary: Cancer immunotherapy has made significant progress in recent years, but low patient response rates and dose-limiting toxicity remain major limitations. Researchers have designed a nanoplatform based on gold nanorods for enhanced photothermal immunotherapy against prostate cancer. The study highlights the importance of synergistic m6A RNA methylation and photothermal therapy in cancer immunotherapy.

ACS APPLIED MATERIALS & INTERFACES (2022)

Article Oncology

Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation

Yung-Hung Luo, Han Liu, Jason A. Wampfler, Henry D. Tazelaar, Yalun Li, Tobias Peikert, Dan Liu, Konstantinos Leventakos, Yuh-Min Chen, Yanan Yang, Shih-Hwa Chiou, Ping Yang

Summary: This study demonstrates that osimertinib as a second or subsequent line of treatment in patients previously treated with EGFR-TKIs without identification of T790M mutation showed a lower risk of death compared to those who received first-line or second-generation TKIs without subsequent osimertinib. Patients with EGFR mutations and PD-L1 expression >= 50% had a higher risk of treatment failure with osimertinib and worse overall survival. These results suggest that osimertinib as a second-line or subsequent treatment may be a potential alternative for patients without identification of T790M, while high PD-L1 expression is associated with poor outcomes in patients receiving osimertinib.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

No Data Available